|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,250,000,000 |
Market
Cap: |
98.98(B) |
Last
Volume: |
12,102,933 |
Avg
Vol: |
11,967,790 |
52
Week Range: |
$43.7 - $69.08 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 11.3 |
Insider 3/6 Months : 11.9 |
|
Guru Rank Number : 97 |
Guru Rank Value : 8.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
Total People Bought |
0 |
2 |
2 |
2 |
Total Buy Transactions |
0 |
3 |
3 |
3 |
Total Shares Sold |
0 |
0 |
18,718 |
681,397 |
Total Sell Value |
$0 |
$0 |
$1,146,397 |
$49,727,684 |
Total People Sold |
0 |
0 |
2 |
6 |
Total Sell Transactions |
0 |
0 |
2 |
12 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
|
2024-04-01 |
4 |
D |
$52.99 |
$63,376 |
D/D |
(1,196) |
5,336 |
|
- |
|
Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
|
2024-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,306 |
6,532 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2024-03-10 |
4 |
D |
$53.79 |
$896,141 |
D/D |
(16,660) |
347,385 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,153) |
359,080 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,784 |
371,312 |
|
- |
|
Gallman Cari |
EVP, Corporate Affairs |
|
2024-03-10 |
4 |
D |
$53.79 |
$37,438 |
D/D |
(696) |
1,432 |
|
- |
|
Gallman Cari |
EVP, Corporate Affairs |
|
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(839) |
1,926 |
|
- |
|
Gallman Cari |
EVP, Corporate Affairs |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,761 |
2,655 |
|
- |
|
Boerner Christopher S. |
Chief Executive Officer |
|
2024-03-10 |
4 |
D |
$53.79 |
$1,043,903 |
D/D |
(19,407) |
101,205 |
|
- |
|
Boerner Christopher S. |
Chief Executive Officer |
|
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,698) |
115,180 |
|
- |
|
Boerner Christopher S. |
Chief Executive Officer |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
54,638 |
129,769 |
|
- |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2024-03-10 |
4 |
D |
$53.79 |
$996,298 |
D/D |
(18,522) |
194,968 |
|
- |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(19,448) |
208,313 |
|
- |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
64,326 |
225,111 |
|
- |
|
Hoch Lynelle |
President, Cell Therapy Org. |
|
2024-03-10 |
4 |
D |
$53.79 |
$70,357 |
D/D |
(1,308) |
1,726 |
|
- |
|
Hoch Lynelle |
President, Cell Therapy Org. |
|
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,317) |
2,643 |
|
- |
|
Hoch Lynelle |
President, Cell Therapy Org. |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,351 |
3,781 |
|
- |
|
Holzer Phil M |
SVP and Controller |
|
2024-03-10 |
4 |
D |
$53.79 |
$74,714 |
D/D |
(1,389) |
12,460 |
|
- |
|
Holzer Phil M |
SVP and Controller |
|
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,682) |
13,452 |
|
- |
|
Holzer Phil M |
SVP and Controller |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,520 |
14,916 |
|
- |
|
Caforio Giovanni |
Executive Chair of the Board |
|
2024-03-10 |
4 |
D |
$53.79 |
$3,648,199 |
D/D |
(67,823) |
432,266 |
|
- |
|
Caforio Giovanni |
Executive Chair of the Board |
|
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(57,536) |
479,917 |
|
- |
|
Caforio Giovanni |
Executive Chair of the Board |
|
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
190,130 |
529,662 |
|
- |
|
Plenge Robert M |
EVP, Chief Research Officer |
|
2024-03-10 |
4 |
D |
$53.79 |
$105,697 |
D/D |
(1,965) |
11,315 |
|
- |
|
Plenge Robert M |
EVP, Chief Research Officer |
|
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,789) |
12,751 |
|
- |
|
956 Records found
|
|
Page 1 of 39 |
|
|